News
Guides, lab handling, storage and research insights from our team.
FDA approval
Aug 07, 2026
Retatrutide vs. Tirzepatide for Obesity Decline: Addressing GLP-1 Misuse Risks Highlighted by DoctorsRetatrutide and tirzepatide are two peptides studied for obesity, but only tirzepatide is FDA-approved. Doctors warn about misuse risks of...Read article
GIP
Jul 22, 2026
Tirzepatide vs. Retatrutide for Menstrual Cycle ChangesTirzepatide and retatrutide are incretin-based therapies with different receptor targets. This article examines their potential effects on menstrual cyclesRead article